Eisai

Eisai announced that it has completed the rolling submission of the Supplemental Biologics License Application (sBLA) to the US…

LITESPARK-011 trial meets primary endpoint of progression-free survival in patients previously treated with anti-PD-1/L1 therapy

The Supplier Engagement Assessment evaluates how effectively companies are working with suppliers to address climate change issues…

The EMA's human medicines committee last year backed Leqembi for a narrower set of patients than those evaluated in a late-stage…

Measuring the Lec-PF concentration in CSF before and after lecanemab treatment may be useful in assessing the efficacy of…

Total Cost of Ownership (TCO) is a crucial focus in the pharma industry, influencing sustainability and competitiveness.…

Subcontinent's regulators and stakeholders to also discuss patient safety, compliance, advanced therapies, and the impact of…

EU regulator cites brain swelling risks, impacting Eisai and Biogen, and sparking concerns over global sales and market perception…

AI-enhanced solutions will help Eisai accelerate data review and reconciliation by 80 per cent

Leqembi is the only approved treatment in China that has shown efficacy in slowing the progression of Alzheimer’s by directly…